Clinical trial • Phase II • Other
VIPOGLANSTAT (GS-248) for Endometriosis
Phase II trial of VIPOGLANSTAT (GS-248) for Endometriosis.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Endometriosis
- Trial Stage
- Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 31-07-2025
- First CTIS Authorization Date
- 21-11-2025
Trial design
Randomised, placebo: 'the placebo formulation for gs-248 is formulated in a capsule without the active ingredient. both vipoglanstat capsules and placebo are identical capsules.' active intervention: vipoglanstat (gs-248) given as two dose arms (two doses investigated) — specific dose levels and schedule not stated in provided material.-controlled Phase II trial across 42 sites in Bulgaria, Hungary, Czechia and others.
- Randomised
- Yes
- Comparator
- Placebo: 'The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.' Active intervention: Vipoglanstat (GS-248) given as two dose arms (two doses investigated) — specific dose levels and schedule not stated in provided material.
- Target Sample Size
- 271
Eligibility
Recruits 271 No vulnerable populations selected (isVulnerablePopulationSelected:false). Participants are adults (premenopausal females 18 to <45). Subject information and informed consent forms are provided (multiple country-specific ICF documents listed, including pregnancy-specific ICFs). Consent is provided by the adult participant..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected:false). Participants are adults (premenopausal females 18 to <45). Subject information and informed consent forms are provided (multiple country-specific ICF documents listed, including pregnancy-specific ICFs). Consent is provided by the adult participant.
Inclusion criteria
- {"criterion_text":"- 1.\tPremenopausal females 18 to <45 years of age at the time of Visit 1."}
- {"criterion_text":"- 2.\tEndometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit 1 based on: 2a.\tSurgical (via direct visualization or biopsy verified) or 2b.\tImaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging [MRI])."}
- {"criterion_text":"- 3.\tHistory of NMPP significantly affecting daily life confirmed at Visit 1."}
- {"criterion_text":"- 4.\tThe participant reports moderate, severe, or very severe pain during non-menstrual days in the month prior to Visit 2, based on PGA-NMPP."}
Exclusion criteria
- {"criterion_text":"- 1. Chronic pelvic pain that is not judged to be primarily related to endometriosis (eg, chronic pelvic infection, interstitial cystitis, nerve entrapments or neuropathies, non-endometriosis-related pelvic adhesive disease, persistent symptomatic ovarian cyst [eg, dermoid], posttubal ligation, symptomatic hydrosalpinx, and vaginismus)."}
- {"criterion_text":"- 2. Has had more than 2 surgical procedures for endometriosis"}
Endpoints
Primary endpoints
- {"endpoint_text":"- 1. Proportion of participants with at least 2.0 points, or at least 30%, reduction of mean worst NMPP NRS score, without increase in opioid rescue medication use, during non-menstrual days, from baseline to the fourth month of treatment.","definition_or_measurement_approach":"Proportion of participants achieving ≥2.0 points or ≥30% reduction in mean worst non-menstrual pelvic pain (NMPP) Numeric Rating Scale (NRS) score from baseline to month 4, without an increase in opioid rescue medication use, measured during non-menstrual days."}
Secondary endpoints
- {"endpoint_text":"- 1. Change in mean worst NMPP NRS score from baseline to the fourth month of treatment","definition_or_measurement_approach":"Change from baseline to month 4 in mean worst NMPP NRS score."}
- {"endpoint_text":"- 2. Proportion of participants with at least 2.0 points, or at least 30%, reduction of mean worst DYS NRS score, without increase in rescue medication use, during menstrual bleeding days, from baseline to the fourth month of treatment.","definition_or_measurement_approach":"Proportion achieving ≥2.0 points or ≥30% reduction in mean worst dysmenorrhea (DYS) NRS score from baseline to month 4 during menstrual bleeding days, without increase in rescue medication use."}
- {"endpoint_text":"- 3. Change in mean worst DYS NRS score from baseline to the fourth month of treatment","definition_or_measurement_approach":"Change from baseline to month 4 in mean worst DYS NRS score."}
- {"endpoint_text":"- 4. Change in EHP-30 score from Visit 3 to Visit 7.","definition_or_measurement_approach":"Change in Endometriosis Health Profile-30 (EHP-30) score between Visit 3 and Visit 7."}
- {"endpoint_text":"- 5. Change in EHP-30 sexual intercourse subscale score from Visit 3 to Visit 7.","definition_or_measurement_approach":"Change in EHP-30 sexual intercourse subscale score between Visit 3 and Visit 7."}
- {"endpoint_text":"- 6. Change in mean daily opioid rescue medication use for NMPP from baseline to the fourth month of treatment.","definition_or_measurement_approach":"Change from baseline to month 4 in mean daily opioid rescue medication use for NMPP."}
- {"endpoint_text":"- 7. Change in mean daily opioid rescue medication use for DYS from baseline to the fourth month of treatment.","definition_or_measurement_approach":"Change from baseline to month 4 in mean daily opioid rescue medication use for DYS."}
- {"endpoint_text":"- 8. AEs.","definition_or_measurement_approach":"Adverse events monitoring (safety endpoint)."}
- {"endpoint_text":"- 9. Safety laboratory variables (clinical chemistry, hematology, and urinalysis).","definition_or_measurement_approach":"Clinical laboratory safety assessments including clinical chemistry, hematology, and urinalysis."}
Recruitment
- Digital Remote Recruitment
- Yes
- Planned Sample Size
- 271
- Recruitment Window Months
- 19
- Consent Approach
- Informed consent provided by adult participants (all subjects are adults: premenopausal females 18 to <45). Country-specific subject information and informed consent forms are listed for Bulgaria, Hungary, Czechia, Poland, Romania, and Italy (multiple L1/L2 ICF documents). Pregnancy-specific ICFs/forms are available per country (pregnancy participant / pregnant partner forms). No assent process is indicated.
Methods
- Country-specific recruitment materials documented: Patient brochures (K2_*_Brochure) for Bulgaria, Hungary, Czechia, Poland, Romania, Italy.
- Patient letters (K2_*_Patient Letter) for multiple countries.
- HCP letters (K2_HU_Recruitment Material_HCP Letter_Hungarian) to healthcare professionals (Hungary).
- Advocacy factsheets (K2_*_Advocacy Factsheet/Advocacy Factbook) — country-specific advocacy materials.
- Recruitment procedures documents (K1_*_Recruitment Procedure) for Bulgaria, Czechia, Poland, Romania, Italy indicate formal procedures.
- Scout email communications and Scout brochures (Czech materials) indicating use of email outreach (Scout Clinical).
Geography
- Total Number Of Sites
- 42
- Total Number Of Participants
- 271
Bulgaria
- Earliest CTIS Part Ii Submission Date
- 07-11-2025
- Latest Decision Or Authorization Date
- 25-11-2025
- Processing Time Days
- 18
- Number Of Sites
- 3
- Number Of Participants
- 34
Sites
- Site Name
- Medical Center Femiclinic EOOD
- Principal Investigator Name
- Ivan Kostov
- Principal Investigator Email
- prof.ivankostovfc@gmail.com
- Contact Person Name
- Ivan Kostov
- Contact Person Email
- prof.ivankostovfc@gmail.com
- Site Name
- Mbal Lyulin EAD
- Department Name
- Department of Gynecology
- Principal Investigator Name
- Teodor Dakov
- Principal Investigator Email
- dr_dakov@mail.bg
- Contact Person Name
- Teodor Dakov
- Contact Person Email
- dr_dakov@mail.bg
- Site Name
- Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
- Department Name
- Department of Obstetrics and Gynecology
- Principal Investigator Name
- Lyubomir Malchev
- Principal Investigator Email
- l.malchev@mbalpuls.bg
- Contact Person Name
- Lyubomir Malchev
- Contact Person Email
- l.malchev@mbalpuls.bg
Hungary
- Earliest CTIS Part Ii Submission Date
- 26-09-2025
- Latest Decision Or Authorization Date
- 24-11-2025
- Processing Time Days
- 59
- Number Of Sites
- 5
- Number Of Participants
- 64
Sites
- Site Name
- MedEnd Kft.
- Principal Investigator Name
- Attila BOKOR
- Principal Investigator Email
- attila.z.bokor@gmail.com
- Contact Person Name
- Attila BOKOR
- Contact Person Email
- attila.z.bokor@gmail.com
- Site Name
- Semmelweis University
- Department Name
- Szülészeti és Nőgyógyászati Klinika
- Principal Investigator Name
- Nándor ÁCS
- Principal Investigator Email
- acs.nandor@med.semmelweis.hu
- Contact Person Name
- Nándor ÁCS
- Contact Person Email
- acs.nandor@med.semmelweis.hu
- Site Name
- TritonLife Magankorhazak Zrt.
- Principal Investigator Name
- Árpád RUCZ
- Principal Investigator Email
- rucz1@hotmail.com
- Contact Person Name
- Árpád RUCZ
- Contact Person Email
- rucz1@hotmail.com
- Site Name
- University Of Debrecen
- Department Name
- Szülészeti és Nőgyógyászati Klinika
- Principal Investigator Name
- Rudolf LAMPÉ
- Principal Investigator Email
- lampe.rudolf@med.unideb.hu
- Contact Person Name
- Rudolf LAMPÉ
- Contact Person Email
- lampe.rudolf@med.unideb.hu
- Site Name
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
- Department Name
- Szülészet – Nőgyógyászati Osztály
- Principal Investigator Name
- István PÉTERFI
- Principal Investigator Email
- istvan.peterfi@gmail.com
- Contact Person Name
- István PÉTERFI
- Contact Person Email
- istvan.peterfi@gmail.com
Czechia
- Earliest CTIS Part Ii Submission Date
- 12-09-2025
- Latest Decision Or Authorization Date
- 24-11-2025
- Processing Time Days
- 73
- Number Of Sites
- 8
- Number Of Participants
- 17
Sites
- Site Name
- Fakultni Nemocnice Kralovske Vinohrady
- Department Name
- Gynekologicko-porodnická klinika
- Principal Investigator Name
- Michael Halaška
- Principal Investigator Email
- michael.halaska@fnkv.cz
- Contact Person Name
- Michael Halaška
- Contact Person Email
- michael.halaska@fnkv.cz
- Site Name
- NEUMED gynekologicka ambulance s.r.o.
- Principal Investigator Name
- David Neubert
- Principal Investigator Email
- neumed@seznam.cz
- Contact Person Name
- David Neubert
- Contact Person Email
- neumed@seznam.cz
- Site Name
- Fakultni Nemocnice Bulovka
- Department Name
- Gynekologicko-porodnická klinika
- Principal Investigator Name
- Peter Koliba
- Principal Investigator Email
- peter.koliba@bulovka.cz
- Contact Person Name
- Peter Koliba
- Contact Person Email
- peter.koliba@bulovka.cz
- Site Name
- Stella-Gyn s.r.o.
- Principal Investigator Name
- Pavlína Šafránková
- Principal Investigator Email
- gynekologievodnany@seznam.cz
- Contact Person Name
- Pavlína Šafránková
- Contact Person Email
- gynekologievodnany@seznam.cz
- Site Name
- Fakultni Nemocnice Brno
- Department Name
- Gynekologicko-porodnická klinika FN Brno
- Principal Investigator Name
- Robert Hudeček
- Principal Investigator Email
- hudecek.robert@fnbrno.cz
- Contact Person Name
- Robert Hudeček
- Contact Person Email
- hudecek.robert@fnbrno.cz
- Site Name
- Gyncare MUDr. Michael Svec s.r.o.
- Principal Investigator Name
- Michael Švec
- Principal Investigator Email
- michaelsvec@seznam.cz
- Contact Person Name
- Michael Švec
- Contact Person Email
- michaelsvec@seznam.cz
- Site Name
- Gynekologie MEDA s.r.o.
- Principal Investigator Name
- Leopold Rotter
- Principal Investigator Email
- rotter@gynmeda.cz
- Contact Person Name
- Leopold Rotter
- Contact Person Email
- rotter@gynmeda.cz
- Site Name
- Fakultni Nemocnice Brno (additional listed site)
- Principal Investigator Name
- Robert Hudeček
- Principal Investigator Email
- hudecek.robert@fnbrno.cz
- Contact Person Name
- Robert Hudeček
- Contact Person Email
- hudecek.robert@fnbrno.cz
Poland
- Earliest CTIS Part Ii Submission Date
- 05-11-2025
- Latest Decision Or Authorization Date
- 24-11-2025
- Processing Time Days
- 19
- Number Of Sites
- 14
- Number Of Participants
- 68
Sites
- Site Name
- Centrum Medyczne Justmed Sp. z o.o.
- Department Name
- ETG JustMed
- Principal Investigator Name
- Wojciech Majkusiak
- Principal Investigator Email
- j.klimkiewicz@etg-network.com
- Contact Person Name
- Wojciech Majkusiak
- Contact Person Email
- j.klimkiewicz@etg-network.com
- Site Name
- Centrum Ginekologii Endokrynologii I Medycyny Rozrodu Artemida Domitrz I Partnerzy Sp. p. Lekarzy
- Principal Investigator Name
- Jacek Szamatowicz
- Principal Investigator Email
- kontakt@artemida-online.pl
- Contact Person Name
- Jacek Szamatowicz
- Contact Person Email
- kontakt@artemida-online.pl
- Site Name
- Lukmed 2 Sp. z o.o.
- Department Name
- ETG Siedlce
- Principal Investigator Name
- Małgorzata Komsta-Goś
- Principal Investigator Email
- m.komstagos@etg-network.com
- Contact Person Name
- Małgorzata Komsta-Goś
- Contact Person Email
- m.komstagos@etg-network.com
- Site Name
- Grażyna Bogutyn Medico Praktyka Lekarska
- Principal Investigator Name
- Grażyna Bogutyn
- Principal Investigator Email
- gbogutyn@post.pl
- Contact Person Name
- Grażyna Bogutyn
- Contact Person Email
- gbogutyn@post.pl
- Site Name
- Niepubliczny Zaklad Opieki Zdrowotnej Medem Wilk Sp. j.
- Department Name
- NZOZ Medem
- Principal Investigator Name
- Krzysztof Wilk
- Principal Investigator Email
- Krzysztof.wilk@onet.pl
- Contact Person Name
- Krzysztof Wilk
- Contact Person Email
- Krzysztof.wilk@onet.pl
- Site Name
- Provita Sp. z o.o.
- Department Name
- Centrum Medyczne Angelius
- Principal Investigator Name
- Mariusz Kiecka
- Principal Investigator Email
- m.kiecka@angelius.org
- Contact Person Name
- Mariusz Kiecka
- Contact Person Email
- m.kiecka@angelius.org
- Site Name
- Specjalistyczna Poradnia Ginekologiczna Janusz Tomaszewski sp.k.
- Principal Investigator Name
- Janusz Tomaszewski
- Principal Investigator Email
- klinika.jtomaszewski@wp.pl
- Contact Person Name
- Janusz Tomaszewski
- Contact Person Email
- klinika.jtomaszewski@wp.pl
- Site Name
- Hlk Sp. z o.o.
- Department Name
- Centrum Medyczne Chodźki
- Principal Investigator Name
- Maciej Paszkowski
- Principal Investigator Email
- mapaszko@tlen.pl
- Contact Person Name
- Maciej Paszkowski
- Contact Person Email
- mapaszko@tlen.pl
- Site Name
- Specjalistyczna Praktyka Lekarska Krzysztof Dynowski
- Principal Investigator Name
- Krzysztof Dynowski
- Principal Investigator Email
- krzysztof.dynowski@interia.pl
- Contact Person Name
- Krzysztof Dynowski
- Contact Person Email
- krzysztof.dynowski@interia.pl
- Site Name
- Provita Sp. z o.o. (Fabryczna 15b)
- Department Name
- Centrum Medyczne Angelius
- Principal Investigator Name
- Mariusz Kiecka
- Principal Investigator Email
- m.kiecka@angelius.org
- Contact Person Name
- Mariusz Kiecka
- Contact Person Email
- m.kiecka@angelius.org
- Site Name
- Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.
- Principal Investigator Name
- Katarzyna Oronowicz
- Principal Investigator Email
- oronowicz@twojaprzychodnia.com
- Contact Person Name
- Katarzyna Oronowicz
- Contact Person Email
- oronowicz@twojaprzychodnia.com
- Site Name
- In Vivo Sp. z o.o.
- Department Name
- IN-VIVO BYDGOSZCZ
- Principal Investigator Name
- Marek Szymański
- Principal Investigator Email
- m.szymanski@in-vivo.pl
- Contact Person Name
- Marek Szymański
- Contact Person Email
- m.szymanski@in-vivo.pl
- Site Name
- Aidport Sp. z o.o.
- Principal Investigator Name
- Krzysztof Szymanowski
- Principal Investigator Email
- rejestracja@aidport.pl
- Contact Person Name
- Krzysztof Szymanowski
- Contact Person Email
- rejestracja@aidport.pl
- Site Name
- Vita Longa Sp. z o.o.
- Department Name
- Niepubliczny Zakład Opieki Zdrowotnej Vita Longa Sp. z o.o.
- Principal Investigator Name
- Małgorzata Janik
- Principal Investigator Email
- biuro@researchsolutions.pl
- Contact Person Name
- Małgorzata Janik
- Contact Person Email
- biuro@researchsolutions.pl
Italy
- Earliest CTIS Part Ii Submission Date
- 25-08-2025
- Latest Decision Or Authorization Date
- 21-11-2025
- Processing Time Days
- 88
- Number Of Sites
- 4
- Number Of Participants
- 30
Sites
- Site Name
- IRCCS Ospedale Policlinico San Martino
- Department Name
- Clinica ostetrica e ginecologica
- Principal Investigator Name
- Angelo Cagnacci
- Principal Investigator Email
- angelo.cagnacci@unige.it
- Contact Person Name
- Angelo Cagnacci
- Contact Person Email
- angelo.cagnacci@unige.it
- Site Name
- ARNAS Civico Di Cristina Benfratelli
- Department Name
- U.O.C. di Ostetricia e Ginecologia
- Principal Investigator Name
- Antonio Maiorana
- Principal Investigator Email
- Antonio.maiorana@arnascivico.it
- Contact Person Name
- Antonio Maiorana
- Contact Person Email
- Antonio.maiorana@arnascivico.it
- Site Name
- Azienda Ospedaliero Universitaria Careggi
- Department Name
- Dipartimento di Scienze Biomediche Sperimentali e Cliniche
- Principal Investigator Name
- Silvia Vannuccini
- Principal Investigator Email
- silvia.vannuccini@unifi.it
- Contact Person Name
- Silvia Vannuccini
- Contact Person Email
- silvia.vannuccini@unifi.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Scienze della salute della donna, del bambino e di sanità pubblica
- Principal Investigator Name
- Alessandra De Cicco Nardone
- Principal Investigator Email
- alessandra.decicconardone@policlinicogemelli.it
- Contact Person Name
- Alessandra De Cicco Nardone
- Contact Person Email
- alessandra.decicconardone@policlinicogemelli.it
Romania
- Earliest CTIS Part Ii Submission Date
- 19-02-2026
- Latest Decision Or Authorization Date
- 16-03-2026
- Processing Time Days
- 25
- Number Of Sites
- 8
- Number Of Participants
- 58
Sites
- Site Name
- Delta Health Care S.R.L.
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Erna Stoian
- Principal Investigator Email
- alis.mihai@reginamaria.com
- Contact Person Name
- Erna Stoian
- Contact Person Email
- alis.mihai@reginamaria.com
- Site Name
- Centrul Medical Unirea S.R.L.
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Ioana Pavaleanu
- Principal Investigator Email
- Ioana_pavaleanu@yahoo.com
- Contact Person Name
- Ioana Pavaleanu
- Contact Person Email
- Ioana_pavaleanu@yahoo.com
- Site Name
- San Medica S.R.L.
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Gheorghita Trusca
- Principal Investigator Email
- leonora.cocosila@clintrial.ro
- Contact Person Name
- Gheorghita Trusca
- Contact Person Email
- leonora.cocosila@clintrial.ro
- Site Name
- Centrul Medical Unirea S.R.L. (Brasov)
- Principal Investigator Name
- Marius Alexandru Moga
- Principal Investigator Email
- brasov@reginamaria.ro
- Contact Person Name
- Marius Alexandru Moga
- Contact Person Email
- brasov@reginamaria.ro
- Site Name
- Genesys Fertility Center S.R.L.
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Aida Tincuta Petca
- Principal Investigator Email
- genesysfertilitycenter@yahoo.com
- Contact Person Name
- Aida Tincuta Petca
- Contact Person Email
- genesysfertilitycenter@yahoo.com
- Site Name
- Quantum Medical Center S.R.L.
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Daniel Tutunaru
- Principal Investigator Email
- daniel.tutunaru@clinicaccbr.com
- Contact Person Name
- Daniel Tutunaru
- Contact Person Email
- daniel.tutunaru@clinicaccbr.com
- Site Name
- Spitalul Clinic Judetean De Urgenta Targu Mures
- Department Name
- Obstetrics-Gynecology
- Principal Investigator Name
- Lucian Puscasiu
- Principal Investigator Email
- secretariat@spitalmures.ro
- Contact Person Name
- Lucian Puscasiu
- Contact Person Email
- secretariat@spitalmures.ro
- Site Name
- Spitalul Clinic Filantropia
- Department Name
- Gynecology
- Principal Investigator Name
- Claudia Mehedintu
- Principal Investigator Email
- office@spitalulfilantropia.ro
- Contact Person Name
- Claudia Mehedintu
- Contact Person Email
- office@spitalulfilantropia.ro
Sponsor
Primary sponsor
- Full Name
- Gesynta Pharma AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Contract research organisations
- Name
- Icon Clinical Research Limited
- Responsibilities
- Multiple sponsor duties (codes listed in CTIS); includes MRI reading
- Name
- Almac Clinical Services Limited
- Responsibilities
- Clinical supplies management. IMP packaging, labelling and batch release
- Name
- Eresearchtechnology Inc.
- Responsibilities
- Sponsor duty code 7 (as listed in CTIS)
Third parties
- {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United Kingdom (Northern Ireland)","full_name":"Almac Clinical Services Limited","duties_or_roles":"Clinical supplies management. IMP packaging, labelling and batch release","organisation_type":"Pharmaceutical company"}
- {"country":"France","full_name":"Quipment","duties_or_roles":"Equipment supplies - freezers","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Eresearchtechnology Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"Patient reimbursement and travel arrangements","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"Multiple sponsor duties (codes provided in CTIS); includes 'MRI reading'","organisation_type":"Pharmaceutical company"}
- {"country":"Sweden","full_name":"Karolinska Institutet Biobank","duties_or_roles":"Biobank","organisation_type":"Industry"}
- {"country":"Sweden","full_name":"Lablytica Life Science AB","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- Vipoglanstat
- Active Substance
- VIPOGLANSTAT (GS-248)
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Investigational Product Name
- GS-248 (alternate name for Vipoglanstat)
- Active Substance
- GS-248
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Investigational Product Name
- The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.
- Modality
- Other
Related trials
Other published trials that may interest you.